Hudson Bay Capital Management LP
Position in GLAS — Glass House Brands Inc.
CIK 1393825
STAMFORD, CT
Position in GLAS
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$9,750,000
New position
Shares Held
750,000
first reported quarter
Ownership
0.796%
of shares outstanding
% of Portfolio
0.05%
of 13F equity value
Holder Rank
#8
of 53 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026Hudson Bay Capital Management LP holds $72,604,865 across 10 Drug Manufacturers - Specialty & Generic names. GLAS ranks #3 (13.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | BHC |
Bausch Health Companies Inc.
|
5,000,000 | $24,650,000 | |
| 2 | NBIX |
Neurocrine Biosciences Inc
|
130,000 | $21,910,200 | |
| 3 | GLAS |
Glass House Brands Inc.
This page
|
750,000 | $9,750,000 | |
| 4 | TAK |
Takeda Pharmaceutical Co Ltd
|
275,000 | $4,408,250 | |
| 5 | BCRX |
Biocryst Pharmaceuticals Inc
|
400,000 | $4,000,000 | |
| 6 | UTHR |
UNITED THERAPEUTICS Corp
|
5,000 | $2,709,150 | |
| 7 | HIMS |
Hims & Hers Health, Inc.
|
70,009 | $2,427,211 | |
| 8 | AQST |
Aquestive Therapeutics, Inc.
|
234,000 | $973,440 |
All Filings in GLAS
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $9,750,000 | 750,000 | Shares | Sole | 2026-08-14 | |
| No filing history on record for this holder in this stock. | ||||||